Abnormal Liver Enzymes: Patterns, the First Work-Up and When to Refer

An abnormal liver panel is worked up in a fixed order: confirm it, name the pattern, grade the severity, and let those two facts choose the first tests. The ACG 2017 guideline defines a hepatocellular pattern (ALT and AST disproportionately raised), a cholestatic pattern (alkaline phosphatase disproportionately raised), a mixed pattern, and isolated hyperbilirubinemia, and grades aminotransferase elevations as borderline (under 2 times the upper limit of normal), mild (2 to 5), moderate (5 to 15) and severe (over 15). Most primary-care elevations are borderline or mild and hepatocellular, and the commonest cause is metabolic dysfunction-associated steatotic liver disease (MASLD), which AASLD 2023 guidance stages with FIB-4 and elastography to decide who needs hepatology.

Step 1: confirm and read the panel

The ACG guideline's first recommendation is to repeat the panel, or run a clarifying test such as GGT for a raised alkaline phosphatase, before starting an evaluation. Liver chemistries fluctuate, and a single borderline value is often normal on repeat.

Read each test for what it reflects:

The ACG 2017 guideline sets a healthy ALT at 29 to 33 IU/L for men and 19 to 25 IU/L for women. Many laboratories use higher limits, so a value reported as normal may still deserve attention in a patient with risk factors.

Step 2: name the pattern

The R ratio formalizes the pattern: R equals (ALT divided by the ALT upper limit of normal) divided by (alkaline phosphatase divided by its upper limit of normal).

Two ratio clues matter for the exam. An AST to ALT ratio of at least 2 to 1, with values rarely above 300 IU/L, points toward alcohol-associated liver disease, and a ratio above 3 to 1 makes it more likely. The guideline defines significant alcohol use as more than 210 g per week for men and more than 140 g per week for women.

Step 3: grade the severity and run the first tests

Borderline (under 2 times ULN) and mild (2 to 5 times ULN) hepatocellular elevation

The ACG algorithm starts with:

• History and examination, including every prescription, over-the-counter drug, herbal product and supplement, and alcohol quantity.
• Stopping hepatotoxic drugs and alcohol where possible.
• CBC with platelets, AST, ALT, alkaline phosphatase, total bilirubin, albumin and PT/INR.
• Hepatitis B surface antigen, hepatitis B core antibody and hepatitis B surface antibody; hepatitis C antibody with HCV RNA confirmation if positive.
• An iron panel (iron, transferrin saturation, ferritin). HFE gene testing follows if transferrin saturation is 45% or higher or ferritin is raised.
• Abdominal ultrasound, which also screens for steatosis in patients with metabolic risk factors.

If this first round is negative, observation with a repeat panel over 3 to 6 months is reasonable. If the elevation persists, the second round includes:

• Autoimmune markers: ANA, anti-smooth muscle antibody and globulin or IgG level.
• Ceruloplasmin for Wilson disease, especially in patients under 55; a low value leads to 24-hour urine copper and slit-lamp examination.
• Alpha-1 antitrypsin phenotype.
• Tests guided by history: celiac serology, thyroid function, creatine kinase for a muscle source.

Liver biopsy is considered when serology and imaging do not explain persistent abnormalities.

Moderate elevation (5 to 15 times ULN)

Everything above applies, plus acute viral hepatitis testing: hepatitis A IgM and hepatitis B core IgM, with hepatitis E considered after travel to an endemic region. Check for signs of acute liver failure.

Severe elevation (over 15 times ULN, or ALT above 10,000 IU/L)

Add acetaminophen toxicity and ischemic hepatopathy (shock liver) to the differential. These patients usually need same-day assessment.

Raised alkaline phosphatase

• Confirm a hepatic source with GGT.
• Ultrasound to look for biliary dilation, stones or masses.
• Anti-mitochondrial antibody for primary biliary cholangitis.
• MR cholangiography for suspected primary sclerosing cholangitis, often with IgG4.
• Review drugs that cause cholestasis.

Isolated raised bilirubin

Fractionate the bilirubin. A mainly unconjugated rise under 4 mg/dL with normal aminotransferases, alkaline phosphatase and blood count, and no hemolysis, is consistent with Gilbert syndrome. It needs reassurance, not further imaging. A conjugated rise needs evaluation for hepatobiliary disease.

Hepatitis C screening

Beyond the abnormal-panel work-up, CDC 2020 recommendations call for one-time hepatitis C screening of every adult 18 or older and every pregnant patient during each pregnancy, so a missing HCV test is always a gap.

MASLD: the most likely answer in primary care

Definition

The 2023 multisociety nomenclature replaced NAFLD with MASLD: hepatic steatosis plus at least one cardiometabolic risk factor (overweight or central obesity, prediabetes or type 2 diabetes, high blood pressure, raised triglycerides, or low HDL cholesterol) without another cause. MetALD describes MASLD with alcohol intake of 140 to 350 g per week in women or 210 to 420 g per week in men. MASH (steatohepatitis) replaces NASH.

Risk stratification

AASLD 2023 guidance uses a stepwise, noninvasive approach in primary care:

FIB-4 is calculated from age, AST, ALT and platelet count. Patients with type 2 diabetes, obesity with metabolic complications, or a first-degree relative with cirrhosis carry a higher risk and deserve active case finding.

Management in primary care

• Weight loss is the core treatment. Loss of about 5% of body weight reduces liver fat, and 10% or more gives the best chance of improving steatohepatitis and fibrosis.
• Diet and activity: a Mediterranean-style eating pattern, reduced added sugar and ultra-processed food, and regular aerobic and resistance exercise.
• Alcohol: limit, and avoid entirely when fibrosis is significant.
• Cardiometabolic risk: treat diabetes, hypertension and dyslipidemia. Statins are safe in MASLD and should not be withheld for mildly raised aminotransferases. In type 2 diabetes or obesity, agents with liver benefit such as GLP-1 receptor agonists and pioglitazone are favored.
• Fibrosis-directed drugs: in March 2024 the FDA approved resmetirom for adults with noncirrhotic MASH and moderate to advanced fibrosis (F2 to F3), alongside diet and exercise. Selection of these patients usually involves hepatology.

Referral and admission triggers

• Immediate referral: acute hepatitis with a prolonged prothrombin time or INR, or any encephalopathy. The ACG guideline treats this as acute liver failure risk requiring urgent specialist and possible transplant-center contact.
• Severe elevation above 15 times normal, suspected acetaminophen toxicity or shock liver: same-day or emergency evaluation.
• Biliary dilation, a mass, or jaundice with a cholestatic pattern.
• Positive hepatitis B surface antigen or HCV RNA, for treatment evaluation if the provider is not managing it.
• Suspected autoimmune hepatitis, Wilson disease, hemochromatosis or primary biliary cholangitis.
• MASLD with indeterminate or high-risk elastography, or any sign of cirrhosis: low platelets, splenomegaly, ascites, varices.
• Persistent unexplained elevation after the full second-round work-up.

Monitoring

• Repeat the panel at the interval the algorithm sets: within weeks for moderate elevation, 3 to 6 months for borderline or mild elevation with a negative first round.
• After stopping a suspected culprit drug or alcohol, a falling ALT supports the diagnosis.
• MASLD: track weight, cardiometabolic control and FIB-4 over time.

Patient and family education

• An abnormal liver test is common and most causes are treatable, but it should not be ignored.
• List every supplement, herbal product and over-the-counter medicine, including acetaminophen, and avoid exceeding labeled doses.
• Alcohol affects the liver at lower amounts in people with fatty liver; abstaining while tests are pending is reasonable.
• Gradual, sustained weight loss of 5 to 10% protects the liver; very rapid loss is not the aim.
• Family members of a patient with hemochromatosis, Wilson disease or hepatitis B may need testing.
• Report yellowing of the eyes, dark urine, confusion, abdominal swelling or easy bruising at once.

How the exam tests this

• Ignoring the pattern. A raised alkaline phosphatase with a normal GGT points to bone, not liver; ordering MRCP is the distractor.
• Missing the AST to ALT ratio. AST twice the ALT, both under 300, in a patient with heavy drinking signals alcohol-associated disease.
• Wrong test for active hepatitis B. Hepatitis B surface antigen identifies infection; surface antibody alone shows immunity.
• Biopsy too early. Biopsy comes after serology, imaging and noninvasive fibrosis testing fail to answer the question.
• Referring every patient with fatty liver. FIB-4 below 1.3 means primary-care management; the referral answer belongs to indeterminate or high-risk elastography.
• Working up Gilbert syndrome. Isolated unconjugated bilirubin with normal enzymes needs reassurance, not CT.
• Missing synthetic dysfunction. A raised INR or confusion with acute hepatitis turns a routine work-up into an urgent referral.
• Stopping a statin. Mildly raised aminotransferases in MASLD are not a reason to stop statin therapy.

Practice question

A 54-year-old man with type 2 diabetes and a BMI of 33 has an ALT of 68 IU/L and AST of 49 IU/L on two occasions 3 months apart. He takes metformin and atorvastatin and drinks 2 beers per week. Hepatitis B surface antigen and hepatitis C antibody are negative, transferrin saturation is 28%, and ultrasound shows diffuse hepatic steatosis without biliary dilation. Platelet count is 182,000/mm3, and his calculated FIB-4 is 1.8. Which of the following is the most appropriate next step?

• A. Refer for liver biopsy
• B. Order vibration-controlled transient elastography
• C. Reassure him and repeat FIB-4 in 3 years
• D. Stop his atorvastatin until the ALT normalizes

Answer: B. He has MASLD, and his FIB-4 of 1.8 is at or above the 1.3 threshold, so AASLD 2023 guidance calls for a second-line test such as transient elastography or ELF before deciding on referral. Biopsy (A) is reserved for cases where noninvasive testing is indeterminate or another diagnosis is suspected. Reassurance with a 3-year interval (C) is appropriate only for a FIB-4 below 1.3, and his diabetes would shorten any interval. Stopping the statin (D) is wrong because statins are safe in MASLD and he has diabetes-related cardiovascular risk.

Key points

Related NPPace guides

• Chronic Kidney Disease for the NP Exam: KDIGO Staging, Albuminuria, Kidney-Protective Drugs and Dose Adjustment
• Genitourinary Presentations in Primary Care: BPH, Overactive Bladder, Urethritis and When to Refer
• GERD and H. pylori on the NP Exam: PPI Trials, Alarm Features, Testing and Eradication Regimens
• How to Read a Primary-Care Vignette Like a Provider: The 5-Step Method
• AANP vs ANCC: Which NP Certification Exam Should You Take?